Dr Alexey Danilov speaks to ecancer about the results from the CLL expansion and optimization cohorts of Epcore CLL-1 study.

This study reveals promising data on the safety and efficacy of monotherapy for patients with relapsed refractory chronic lymphocytic leukaemia (CLL).

It includes two cohorts, showing that epcoritamab is well tolerated with rare treatment discontinuations.

The expansion cohort reports a 67% response rate, especially in high-risk patients.

The findings emphasise the need for better treatment options and suggest that bispecific T cell engagement technology could enhance outcomes for double refractory CLL.